Glaukos Stock

Glaukos FCF per Share

The Free Cash Flow per Share of Glaukos (GKOS) as of Aug 17, 2026 is -0.94 USD. In the previous year, Free Cash Flow per Share was -1.22 USD — a change of -22.80% (higher).

FCF per Share

-0.94USD

YoY

-22.80%

Last updated:

Free Cash Flow per Share of Glaukos is 2026 -0.94 USD. Free Cash Flow per Share of Glaukos was 2025 -1.22 USD. It decreases by -22.80% higher compared to the previous year.
Access this data via the Eulerpool API

Glaukos Stock analysis

What does Glaukos do? Glaukos Corp is a medical technology company specializing in developing devices and therapies for treating eye diseases. It was founded in 1998 by employees of the ophthalmology center at the University of California San Francisco. The company focuses on utilizing new technologies and therapies to improve the vision quality of patients. They have developed innovative products for diagnosing and treating various eye conditions, including glaucoma. Their core business involves manufacturing and distributing medical devices for glaucoma treatment, such as the iStent implant. They have also partnered with other institutions to advance research and development in the field of ophthalmology. In 2018, Glaukos Corp acquired the German manufacturer Markt II Medical, expanding their product offerings for a wider range of eye diseases. In summary, Glaukos Corp is an innovative medical technology company that aims to enhance patients' vision quality while minimizing the risks of eye surgery. Glaukos is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Glaukos stock

Free Cash Flow per Share of Glaukos is -0.94 USD in 2026.

Free Cash Flow per Share of Glaukos changed from -1.22 USD to -0.94 USD, representing a -22.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Glaukos since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

Cash Flow — Glaukos

All Key Metrics — Glaukos